Kiniksa Pharmaceuticals International (KNSA) Gross Margin (2021 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Gross Margin came in at 90.32% in Q2 2026, up 219.0% YoY from 28.31% in Q2 2025, and little changed on a QoQ basis from 90.29% in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Gross Margin (2021 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 6 years of Gross Margin data on file, last reported at 90.32% in Q2 2026.
- Quarterly Gross Margin rose 219.0% year-over-year to 90.32% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 89.82% (up 389.0% YoY) and the FY2025 annual result came in at 88.54%, up 293.0% from the prior year.
- Gross Margin steadied at 90.32% in Q2 2026, from 90.29% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 104.52% in Q4 2022 to a low of 81.35% in Q2 2022.
- A 5-year average of 89.22% and a median of 88.58% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin surged 2515 bps — and 2023, when it tumbled 1602 bps.
- Tracing KNSA's Gross Margin over 5 years: stood at 104.52% in 2022, then decreased by 15 bps to 88.51% in 2023, then declined by 4 bps to 85.4% in 2024, then increased by 5 bps to 89.64% in 2025, then rose by 1 bps to 90.32% in 2026.
- The last three Gross Margin figures came in at 90.32% (Q2 2026), 90.29% (Q1 2026), and 89.64% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.57 Bn | 220.03 Mn | 90.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.32% |
| Mar 31, 2026 | 90.29% |
| Dec 31, 2025 | 89.64% |
| Sep 30, 2025 | 88.80% |
| Jun 30, 2025 | 88.14% |
| Mar 31, 2025 | 87.03% |
| Dec 31, 2024 | 85.40% |
| Sep 30, 2024 | 82.08% |
| Jun 30, 2024 | 88.66% |
| Mar 31, 2024 | 86.75% |
| Dec 31, 2023 | 88.51% |
| Sep 30, 2023 | 86.45% |
| Jun 30, 2023 | 89.23% |
| Mar 31, 2023 | 98.98% |
| Dec 31, 2022 | 104.52% |
| Sep 30, 2022 | 93.00% |
| Jun 30, 2022 | 81.35% |
| Mar 31, 2022 | 86.89% |
| Dec 31, 2021 | 79.37% |
| Sep 30, 2021 | 77.12% |